Touchlight will expand Lonza’s end-to-end offering for mRNA manufacturing with an additional, differentiated source of DNA raw material.

The patent applications are for programs concerning lupus, idiopathic pulmonary fibrosis, and chronic kidney disease.

A new survey has demonstrated that remote audits, brought to the fore thanks to COVID-19, are not necessarily a preferred option for clients.

Hovione has expanded its drug product offering with a new manufacturing line dedicated to continuous tableting.

Novo Nordisk’s $1.1 billion acquisition of Forma Therapeutics is intended to expand its sickle cell and rare blood disorder portfolio.

FDA has issued an emergency use authorization for both the Pfizer-BioNTech and Moderna bivalent COVID-19 boosters.

Bio-Rad’s new antibodies are designed to develop highly selective pharmacokinetic (PK) and anti-drug antibody (ADA) assays for evolocumab and its biosimilars.

Roche’s Digital LightCycler System is designed to aid in diagnostics for cancer, genetic disease, and infection.

More than anything else MonkeyPox and COVID-19 have shown that we are interdependent, no matter what continent you call home.

While the cost of certain medicines are alarmingly high, they can be considered a bargain measured against a lifetime of traditional costs.

Lonza has introduced X-ray powder diffraction capability at its Monteggio, Switzerland site.

Forecyte Bio and Cytiva will team up to accelerate the development and manufacturing of cell and gene therapies.

Emerson’s new gas analysis solutions center, located in Cumbernauld, Scotland, intends to help plants meet sustainability goals.

Thermo Fisher Scientific’s new 300,000 ft² facility, located in Plainville, Mass., will specialize in manufacturing viral vectors.

Scientists have developed a mouse model that could be a promising model system for research into factors affecting mammalian embryonic development and disease.

Novavax’s COVID-19 vaccine, Nuvaxovid, can now be given to adolescents aged 12 to 17 in the UK.

Canvax’s new inorganic pyrophosphate is designed for in-vitro transcription reactions.

The European Union publishes long-awaited changes to Annex 1.

Moderna is suing Pfizer and BioNTech for allegedly infringing on patents the company filed from 2010 to 2016.

Watson-Marlow and Franz Ziel GmbH have launched a new integrated solution to fast-track cell, gene, and biological therapies.

ChargePoint Technology has acquired single-use container company PuroVaso.

Anthony Fauci announced that he plans to step down as Director of the National Institute of Allergy and Infectious Diseases in December 2022.

Aerie to be purchased by Alcon after recently bringing two glaucoma drugs to market.

NICE has recommended the use of Tavneos (avacopan) in combination with rituximab or cyclophosphamide regimen.

Kapruvia (difelikefalin) has been granted approval by Swissmedic as a treatment for moderate-to-severe pruritis associated with CKD.

The European Commission (EC) has approved Celltrion Healthcare's Vegzelma (CT-P16), a biosimilar to bevacizumab referencing Avastin.

The latest CPHI report has been published, predicting that a significant shift in outsourcing strategies is being experienced globally.

EMA has accepted the marketing authorization application for an oral fixed-dose combination treatment as an initial treatment for adults with AML.